It is noteworthy that most of the published studies on NKG2D CAR-T/NK therapy have been focused on solid tumors, particularly brain tumors, breast cancer, lung cancers, gastrointestinal tracts, reproductive system, and sarcomas. This evidence concerns the gene KLRK1 and lung carcinoma.